Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CEACAM-1


Brief Information

Name:Carcinoembryonic antigen related cell adhesion molecule 1
Target Synonym:CEACAM1,Biliary glycoprotein 1,BGP,CD66a,Carcinoembryonic Antigen Related Cell Adhesion Molecule 1,CD66a Antigen,BGP1,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1,Antigen CD66,BGP-1,BGPI,CEA Cell Adhesion Molecule 1,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (Biliary Glycoprotein)
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data


Immobilized Human CEACAM-1, His Tag (Cat. No. CE1-H5220) at 10 μg/mL (100 μL/well) can bind Biotinylated Human CEACAM-8, His,Avitag (Cat. No. CE8-H82E9) with a linear range of 0.039-1.25 μg/mL (QC tested).

Biotinylated Human CEACAM-1, Avitag,His TagBiotinylated Human CEACAM-1, Avitag,His Tag (Cat. No. CE1-H82E5) ELISA bioactivity

Immobilized Human CD209, His Tag (Cat. No. CD9-H5246) at 5 μg/mL (100 μL/well) can bind Biotinylated Human CEACAM-1, Avitag,His Tag (Cat. No. CE1-H82E5) with a linear range of 10-78 ng/mL (QC tested).

Synonym Name



Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is also known as Biliary glycoprotein 1 (BGP1), CD66a,  which belongs to the immunoglobulin superfamily or CEA family. CEACAM1 /CD66a contains three Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. CEACAM1 /CD66a was described as an adhesion molecule mediating cell adhesion via both homophilic and heterophilic manners, and was detected on leukocytes, epithelia, and endothelia. Studies have revealed that CEACAM1 / BGP-1 performs actions in multiple cellular processes including tissue differentiation, angiogenesis, apoptosis, metastasis, as well as the modulation of innate and adaptive immune responses.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CM-24 CM-24 (MK-6018); MK-6018; CM-24 Phase 2 Clinical Merck Sharp & Dohme Corp Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Thyroid Cancer, Papillary Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message